|
| Compounds | Constituents | Effects on research fields |
|
| SAC | S-allylcysteine | Protection on cardiovascular and neural systems |
| SPRC | S-propargyl-cysteine | Anticancer, anti-inflammation, and antihypoxic/ischemia and impairs cognition and Aβ-induced neuronal damage |
| GYY4137 | Morpholin-4-ium-4-methoxyphenyl (morpholino) phosphinodithioate | Antagonizes endotoxic shock though anti-inflammatory effects |
| ACS-6 | A H2S-donating sildenafil | Inhibits superoxide formation and gp91phox expression in porcine PAECs |
| ACS-14 | A H2S-releasing aspirin | Regulates redox imbalance, such as GSH formation, HO-1 promoter activity, and isoprostane suppression |
| ACS-15 | A H2S-releasing derivative of diclofenac | Arthritis |
| ACS-67 | A H2S-releasing derivative of latanoprost acid | Glaucoma; retinal ischemia |
| ATB-284 | A H2S-releasing derivative of trimebutine | Irritable bowel syndrome |
| ATB-337 | A H2S-releasing derivative of diclofenac | Gastrointestinal damage induced by NSAIDs |
| ATB-346 | A H2S-releasing derivative of naproxen | Acute and chronic joint pain |
| ATB-429 | A H2S-releasing derivative of mesalamine | Inflammatory bowel disease and antinociceptive and anti-inflammatory effects |
| IK 1001 | Calcium-cross-linked alginate polymer | Suspended animation, multiple hypoxic/ischemic conditions, cardiac remodeling, and congestive heart failure |
|
